Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994

Clinical Infectious Diseases

Volumn 23, Issue SUPPL. 1, 1996, Pages

  Snydman, David R ^a   McDermott, Laura ^b   Cuchural Jr , George J ^b   Hecht, David W ^b   Iannini, Paul B ^b   Harrell, Lizzie J ^b   Jenkins, Stephen G ^b   O'Keefe, J Paul ^b   Pierson, Carl L ^b   Rihs, John D ^b   Yu, Victor L ^b   Finegold, Sydney M ^b   Gorbach, Sherwood L ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFMETAZOLE; CEFOTETAN; CEFOXITIN; CEFTIZOXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

EID: 19244364519     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.supplement_1.s54     Document Type: Article

References (9)

1. Dubreuil L, Breuil J, Duals A, Se A. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis 1992;11:1094-9.
2. Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother 1984;26:145-8.
3. Tanaka-Bandoh K, Kato N, Watanabe K, Ueno K. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992. Clin Infect Dis 1995;20(suppl 2):S352-5.
4. Betriu C, Cabronero C, Gomez M, Picazo JJ. Changes in the susceptibility of the Bacteroides fragilis group organisms to various antimicrobial agents, 1979-1989. Eur J Clin Microbiol Infect Dis 1992;11:352-6.
5. Snydman DR, Cuchural GJ Jr, The National Anaerobic Susceptibility Study Group. Susceptibility variations in Bacteroides fragilis: a national survey. Infect Dis Clin Pract 1994;3(suppl 1):S34-43.
6. Redondo MC, Arbo MDJ, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995;20:1492-6.
7. Brook I. Recovery of anaerobic bacteria from clinical specimens in 12 years at two military hospitals. J Clin Microbiol 1988;26:1181-8.
8. Gorbach SL, Bartlett JG. Anaerobic infections [parts 1 and 2]. N Engl J Med 1974;290:1177-84, 1237-45.
9. Snydman DR, Cuchural GJ Jr, McDermott L, Gill M. Correlation of various in-vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 1992;36:540-4.